Page 83 - Priority Review News Today

(The Center Square) – The U.S. Food and Drug Administration accepted Emergent BioSolutions request to review its supplemental New Drug Application for the NARCAN® Nasal Spray to be sold as an over-the-counter emergency treatment for known or suspected opioid overdose, the company said Tuesday.

The FDA has accepted for Priority Review the sNDA for Narcan (naloxone HCl) Nasal Spray as an OTC emergency treatment.

(The Center Square) – The U.S. Food and Drug Administration accepted Emergent BioSolutions request to review its supplemental New Drug Application for the NARCAN® Nasal Spray to be sold as

SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. ... | December 5, 2022

WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday that the European Medicines Agency or EMA has accepted the Marketing Authorization Application or MAA for review of tofersen to treat rare

05.12.2022 - -  The program will allow physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States -  TransCon PTH is under Priority Review by the FDA, with a ... Seite 1

VA-accredited claims agent Brett Buchanan of Allsup shares common mistakes to avoid when veterans are filing disability benefits claims.

The FDA has accepted for Priority Review NDA for sulbactam-durlobactam for the treatment of Acinetobacter infections.

The FDA has accepted for Priority Review the BLA for SRP-9001 (delandistrogene moxeparvovec) for ambulant individuals with DMD.

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...